• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Current Status and Future Perspectives of Tegoprazan-Based Eradication Therapy].

作者信息

Noh Jin Hee

出版信息

Korean J Helicobacter Up Gastrointest Res. 2024 Jun;24(2):100-102. doi: 10.7704/kjhugr.2024.0023. Epub 2024 Jun 10.

DOI:10.7704/kjhugr.2024.0023
PMID:40502840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11967494/
Abstract
摘要

相似文献

1
[Current Status and Future Perspectives of Tegoprazan-Based Eradication Therapy].[基于替戈拉赞的根除治疗的现状与未来展望]
Korean J Helicobacter Up Gastrointest Res. 2024 Jun;24(2):100-102. doi: 10.7704/kjhugr.2024.0023. Epub 2024 Jun 10.
2
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of : A Real-World Evidence Study.14 天替戈拉赞与雷贝拉唑三联疗法根除幽门螺杆菌的疗效和耐受性：一项真实世界证据研究。
Gut Liver. 2023 Sep 15;17(5):711-721. doi: 10.5009/gnl220218. Epub 2022 Dec 13.
3
Efficacy of Tegoprazan-Containing Sequential Eradication Treatment Compared to Esomeprazole-Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study.含替戈拉赞的序贯疗法与含埃索美拉唑的序贯疗法根除幽门螺杆菌的疗效比较：韩国高耐药率地区的一项前瞻性、随机、单中心研究。
Helicobacter. 2024 Sep-Oct;29(5):e13143. doi: 10.1111/hel.13143.
4
Comparative efficacy of Helicobacter pylori eradication therapy between tegoprazan-based concomitant and bismuth quadruple therapies: A real-world evidence.基于替戈拉赞的联合疗法与铋剂四联疗法根除幽门螺杆菌的疗效比较：一项真实世界证据
J Gastroenterol Hepatol. 2025 Jan;40(1):159-165. doi: 10.1111/jgh.16798. Epub 2024 Nov 18.
5
Efficacy and safety of tegoprazan- and rabeprazole-based concomitant therapies for Helicobacter pylori infection: Real-world evidence.替戈拉赞和雷贝拉唑联合疗法治疗幽门螺杆菌感染的疗效和安全性：真实世界证据。
J Gastroenterol Hepatol. 2024 Nov;39(11):2409-2416. doi: 10.1111/jgh.16719. Epub 2024 Aug 26.
6
Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China.替戈拉赞-阿莫西林双联疗法根除幽门螺杆菌：中国福建的一项前瞻性、随机、多中心研究。
Helicobacter. 2024 Nov-Dec;29(6):e13151. doi: 10.1111/hel.13151.
7
Comparative Efficacy of Tegoprazan vs Esomeprazole/Sodium Bicarbonate for the Treatment of Helicobacter pylori Infection.替戈拉赞与埃索美拉唑/碳酸氢钠治疗幽门螺杆菌感染的疗效比较。
Clin Transl Gastroenterol. 2023 Nov 1;14(11):e00632. doi: 10.14309/ctg.0000000000000632.
8
Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Eradication.基于替戈拉赞的14天三联疗法与基于替戈拉赞的10天联合疗法根除幽门螺杆菌的疗效比较
J Pers Med. 2022 Nov 17;12(11):1918. doi: 10.3390/jpm12111918.
9
7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence.7 天与 14 天替戈拉赞三联疗法治疗幽门螺杆菌感染：真实世界证据。
J Gastroenterol Hepatol. 2022 Oct;37(10):1911-1918. doi: 10.1111/jgh.15939. Epub 2022 Jul 19.
10
Tegoprazan-Containing Versus Proton Pump Inhibitor-Containing Therapy for First-Line Eradication of : A Meta-Analysis of Randomized Controlled Trials.含替戈拉赞与含质子泵抑制剂疗法用于一线根除幽门螺杆菌的随机对照试验的荟萃分析
JGH Open. 2025 Mar 12;9(3):e70134. doi: 10.1002/jgh3.70134. eCollection 2025 Mar.

本文引用的文献

1
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of : A Real-World Evidence Study.14 天替戈拉赞与雷贝拉唑三联疗法根除幽门螺杆菌的疗效和耐受性：一项真实世界证据研究。
Gut Liver. 2023 Sep 15;17(5):711-721. doi: 10.5009/gnl220218. Epub 2022 Dec 13.
2
7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence.7 天与 14 天替戈拉赞三联疗法治疗幽门螺杆菌感染：真实世界证据。
J Gastroenterol Hepatol. 2022 Oct;37(10):1911-1918. doi: 10.1111/jgh.15939. Epub 2022 Jul 19.
3
Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Infection: A Randomized, Double-Blind, Phase III, Clinical Trial.基于新型钾离子竞争性酸阻滞剂替戈拉赞的三联疗法用于一线治疗感染：一项随机、双盲、III 期临床试验。
Gut Liver. 2022 Jul 15;16(4):535-546. doi: 10.5009/gnl220055. Epub 2022 Jul 6.
4
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.Vonoprazan 三联和双联疗法治疗美国和欧洲的幽门螺杆菌感染：随机临床试验。
Gastroenterology. 2022 Sep;163(3):608-619. doi: 10.1053/j.gastro.2022.05.055. Epub 2022 Jun 6.
5
Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.韩国 2020 年幽门螺杆菌感染治疗的循证指南。
Korean J Intern Med. 2021 Jul;36(4):807-838. doi: 10.3904/kjim.2020.701. Epub 2021 Jun 8.
6
Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.系统评价与荟萃分析：强效酸抑制剂——沃诺拉赞优于质子泵抑制剂，可根除克拉霉素耐药的幽门螺杆菌菌株。
Helicobacter. 2018 Aug;23(4):e12495. doi: 10.1111/hel.12495. Epub 2018 Jun 6.
7
Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?综述：基于日本人群的 vonoprazan 与 PPI 对比治疗幽门螺杆菌根除疗法的荟萃分析：优势是否只是一种假象？
Helicobacter. 2017 Dec;22(6). doi: 10.1111/hel.12438. Epub 2017 Sep 8.
8
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Eradication: A Randomized Controlled Trial.基于 vonoprazan 的方案比基于 PPI 的方案更有用作为一线根除：一项随机对照试验。
Can J Gastroenterol Hepatol. 2017;2017:4385161. doi: 10.1155/2017/4385161. Epub 2017 Feb 28.
9
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.沃克（富马酸沃克替唑胺），一种新型钾离子竞争性酸阻滞剂，作为一线和二线三联疗法的组成部分用于根除幽门螺杆菌：一项III期随机双盲研究。
Gut. 2016 Sep;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304. Epub 2016 Mar 2.
10
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.健康日本/非日本男性受试者单次递增剂量TAK-438（沃克拉唑）的安全性、耐受性、药代动力学和药效学
Clin Transl Gastroenterol. 2015 Jun 25;6(6):e94. doi: 10.1038/ctg.2015.18.